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 3β-Hydroxysteroid dehydrogenase (3β-HSD) is a key 
enzyme in steroidogenesis, responsible for the conversion 
of Δ5- to Δ4-steroids. Thus, it converts the Δ5-steroids 
pregnenolone, 17OH-pregnenolone, dehydroepiandros-
terone (DHEA), and androstenediol to the Δ4-steroids 
progesterone, 17OH-progesterone (17OHP), androstene-
dione, and testosterone, respectively [Simard et al., 1995]. 
In humans, the enzyme exists in 2 isoforms, type 1 being 
expressed in the placenta and peripheral tissues, and type 
2 in adrenals and gonads [Simard et al., 1995].
 Deficiency in 3β-HSD type 2 leads to a rare form of con-
genital adrenal hyperplasia (CAH). Complete loss of func-
tion of the enzyme is responsible for adrenal crisis in the 
newborn, including hypocortisolism and salt loss. Genital 
development is impaired in males, ranging from hypospa-
dias to 46,XY disorder of sex development with nearly fe-
male appearing external genitalia [Simard et al., 2005]. Fe-
males with 3β-HSD type 2 (3β-HSD II) deficiency present 
with no or mild virilization by means of elevated Δ5-
steroids that are peripherally converted to androgens by 
activity of the type 1 isoenzyme of 3β-HSD [Simard et al., 
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 Abstract 
 Classic 3β-hydroxysteroid dehydrogenase type 2 (3β-HSD II) 
deficiency causes congenital adrenal hyperplasia with glu-
cocorticoid, mineralocorticoid, and sex steroid deficiency. 
We present a female patient with congenital adrenal hyper-
plasia detected in newborn screening due to elevated 17OH-
progesterone. Female external genitalia and non-measur-
able androgen levels elicited the suspicion of a defect early 
in the steroid cascade. Two loss-of-function  HSD3B2 muta-
tions (1 novel) were detected and confirmed in silico. We ar-
gue that in a girl with glucocorticoid and mineralocorticoid 
deficiency without virilization, 3β-HSD II deficiency is an im-
portant differential diagnosis. 17OH-progesterone may ini-
tially be elevated due to placental and peripheral activity of 
3β-HSD I, whereas dehydroepiandrosterone may not be in-
creased.  © 2016 S. Karger AG, Basel 
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1995, 2005]. The typical presentation of the non-salt-los-
ing forms is premature pubarche in both sexes.
 The molecular etiology of 3β-HSD deficiency lies in a 
defect in the  HSD3B2 gene, coding for the isoform II of 
the enzyme (type 2) [Rheaume et al., 1995].
 Case Report 
 A healthy full-term female neonate, born to a non-consanguin-
eous couple from Eastern Switzerland, was admitted to our pedi-
atric endocrine service on day 8 of life for further evaluation of 
increased 17OHP in newborn screening. She presented in no phys-
ical distress, feeding well and gaining weight appropriately.
 On clinical examination, we found normal female external geni-
talia without virilization or palpable gonads. Ultrasound revealed 
female internal genitalia with a slightly stimulated uterus and normal 
ovaries with few follicles. Biochemical analyses revealed increased 
adrenocorticotropic hormone with low cortisol, increased 17OHP, 
normal DHEA, 11-deoxycortisol, and increased renin ( table 1 ).
 For suspected CAH with glucocorticoid deficiency, the patient 
was started on hydrocortisone (HC) immediately. The following 
day, she developed salt loss (Na 129 mmol/l, K 6.1 mmol/l) and was 
therefore also started on fludrocortisone (FC) and NaCl supple-
ments ( table 1 ). On continuous HC and FC replacement, psycho-
motor and physical development was normal.
 At 7 months of age, the patient was admitted to the hospital for 
further evaluation: HC and FC were discontinued. Serum steroids 
were measured 36 h after the last dose of HC and FC. Results con-
firmed glucocorticoid and mineralocorticoid deficiency ( table 1 ). 
However, there was no increase in 17OHP or androgens. Due to 
the severe lack of all steroid hormones, we suspected a defect high 
up in the steroid cascade.
 Results 
 Genetic Analysis 
 Genetic analysis revealed that the patient was com-
pound heterozygous for 2 mutations in the  HSD3B2 gene 
( fig. 1 A). One mutation (c.503delC) caused a frameshift 
leading to a premature stop codon (A168Vfs * 6). The oth-
er was a nonsense (stop) mutation shortly after the first 
one (c.512G>A; W171X). The combination of both mu-
tations was considered to cause the phenotype of the pa-
tient.
 Both mutations lead to a shorter and aberrant gene 
product. The normal peptide product is 285 amino acids 
long, whereas the frameshift A168Vfs * 6 mutation coded 
for a peptide of 172 amino acids and the stop W171X mu-
tation for a 170 amino acid peptide ( fig. 1 B). The parents 
were heterozygous for the 2 mutations ( fig.  1 A). Two 
years later, a brother was born with normal male external 
genitalia and a normal urinary steroid profile at birth. The 
genetic analysis showed that he was heterozygous for the 
A168Vfs * 6 paternal mutation ( fig. 1 A).
 In silico Analysis 
 The 2 mutations were further analyzed in silico. We 
analyzed the human HSD3B2 peptide residues 167–173 
involved in the mutations by sequence alignment ( fig. 2 ) 
and structural modeling ( fig. 3 ). The 2 mutations were 
checked by comparing the positions of these amino acids 
in different mammalian HSD3B sequences ( fig.  2 A). 
Table 1.  Biochemical values of the patient at different ages
4 days, 
NBS
8 days 9 days 19 days 5 weeks 11 weeks 6 months 7 months, 
36 h without 
medications
Na, mmol/l 136 129↓
K, mmol/l 5.8 6.1↑
17OHP, nmol/l 244↑ 124↑ 32.7↑ 26.9↑ <0.21 3.8 5.0
11-DOC, nmol/l 54 2.5
DHEA, nmol/l 5.0
DHEA-S, μmol/l 12 <0.41 <0.41 <0.41
D4A, nmol/l <1.05 <1.05 <1.05
ACTH, ng/l 549↑ 490↑
Cortisol, nmol/l 92↓ <28↓
Renin, pg/ml 116 1,414↑
Aldo, pmol/l 1804 93↓
HC p.o., mg/m2/day → 30 30 20 17 16.7 15 14
FC p.o., mg/day → 0.2 0.2 0.15 0.1 0.1 0.05
 Arrows indicate higher (↑) or lower (↓) values. NBS = Newborn screening; 11-DOC = 11-deoxycortisol; DHEA-S = dehydroepi-
androsterone sulfate; D4A = androstenedione; ACTH = adrenocorticotropic hormone; Aldo = aldosterone; → = first dose. 
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 Fig. 1. Genetic analysis of the  HSD3B2 
gene.  A Two mutations in the  HSD3B2 
gene of the patient were detected. One was 
a 1-bp deletion responsible for a shift of the 
reading frame causing 5 amino acid chang-
es followed by a stop codon (c.503delC; 
A168Vfs * 6). The other mutation, only
9 nucleotides downstream, was a 1-bp 
change which produced a stop codon 
(c.512G>A; W171X). The parents present-
ed 1 mutation each and the younger broth-
er the paternal mutation. The  HSD3B2 
gene was amplified (exonic coding se-
quences including intronic boundaries)
using specific primers and PCR amplifi-
cation protocols as described elsewhere. 
Obtained sequences were compared to 
NG_013349.1 (http://www.ncbi.nlm.nih.
gov/).  B The  HSD3B2  gene alleles of the pa-
tient code for 2 different peptide sequences, 
both shorter than the wild type. 
 Fig. 2. Partial sequence alignment and sec-
ondary structure prediction of the HSD3B2 
protein.  A Human HSD3B2 was partially 
aligned with homologous sequences from 6 
mammalian species. Position A168 is con-
served among different species, whereas po-
sition W171 is replaced with S171 in mouse 
and rat. The alignment of the HSD3B2 ami-
no acid sequence (P26439) was adapted 
from the UniProt database, and the other 
mammalian sequences were also available 
in the same database (www.uniprot.org). 
Human:  Homo sapiens; Canfa: dog,  Canis 
familiaris ; Pig:  Sus scrofa ; Bovine: cattle,  Bos 
taurus ; Mouse:  Mus musculus ; Rat:  Rattus 
norvegicus; Macmu: Rhesus macaque,  Ma-
caca mulatta .  B Prediction of the secondary 
structure of the HSD3B2 protein. The posi-
tions of A168Vfs * 6 and W171X and previ-
ously reported mutations are highlighted. 
All these mutations are close to the alpha he-
lix and coil region predicted with the confi-
dence value (depicted in line 3). W171 and 
L173 are predicted to be located in a disor-
dered region, indicated by question marks. 
Prediction of the secondary structure was 
obtained from the Phyre2 server [Kelley and 
Sternberg, 2009]. The first line indicates the 
amino acid sequence and the second line the 
secondary structure prediction. 
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Amino acid A168 is well conserved across all the species, 
but tryptophan at position 171 is substituted with serine 
in mouse and rat species ( fig. 2 A). The structural studies 
showed that amino acids 167–173 are located in the alpha 
helix and coil region of the protein and are close to the ac-
tive site and NAD-binding site of the HSD3B2 protein 
( fig. 3 ). We suggest that the A168Vfs * 6 and W171X mu-
tations lead to truncated HSD3B2 proteins without en-
zymatic activity. Other previously reported mutations, 
A167V and L173R, are located in the vicinity of our pa-
tient’s mutations ( fig. 3 ), A167V not having a major effect 
on the native structure of HSD3B2 [Nayak et al., 1998; 
Moisan et al., 1999], whereas heterozygous L173R re-
duced 3β-HSD enzyme activity by half [Russell et al., 1994; 
Moisan et al., 1999]. Our analysis predicted that L173R is 
located in a disordered region of the protein ( fig. 2 B).
 Discussion 
 We describe a patient with a novel  HSD3B2 mutation 
(A168Vfs * 6) and a previously reported one (W171X). 
The latter (maternal mutation) was described 20 years 
ago in 2 families also from Eastern Switzerland [Rheaume 
et al., 1992]. We were able to track medical records and 
suspect a familial relation. Patients in these families, who 
carried the mutation in a homozygous fashion, presented 
with a classic form of 3β-HSD deficiency with severe salt 
wasting.
 Our female patient was diagnosed with severe gluco-
corticoid and mineralocorticoid deficiency in newborn 
screening due to elevated 17OHP. The lack of androgens 
as well as the completely normal female genitalia made 
us suspect a defect high up in the steroid cascade. By mo-
lecular analysis, our patient could be diagnosed with a 
compound heterozygous  HSD3B2  defect. The increase in 
17OHP could be interpreted as a product of placental 
activity of the isoform I of 3β-HSD. Surprisingly, DHEA 
was not elevated at birth or at 7 months after discontinu-
ation of treatment, probably due to the remaining activ-
ity of 3β-HSD I or to the conversion in the periphery also 
of 3β-HSD I. We expect an increase in DHEA during 
adrenarche with otherwise absent increase in steroid 
hormones and lack of spontaneous pubertal develop-
ment.
 Conclusion 
 In a female CAH patient without virilization, 3β-HSD 
II deficiency must be considered. 17OHP can be elevated 
in the first few days of life due to placental and periph-
eral 3β-HSD I activity. DHEA is not necessarily in-
creased.
 We report a novel HSD3B2 mutation, c.503delC, clin-
ically causing a severe impairment of 3β-HSD II activity 
and leading to a nearly complete deficiency in glucocor-
ticoids, mineralocorticoids, and sex steroids in our phe-
notypically non-virilized female CAH patient.
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 Fig. 3. Structure of HSD3B2. The positions of A168Vfs * 6 and 
W171X and the previously reported mutations A167V and L173R 
(circled and magnified) are highlighted in the 3D model structure 
of the HSD2B2 protein. The N-terminal (N) and C-terminal (C) 
ends are indicated, and the amino acid region from 167 to 173 is 
encircled and shown in a larger resolution. The position of amino 
acid 158 for NAD-ligand binding sites is shown in the central ball 
shape (based on the UniProt database). The 3D model structure 
was obtained using the HSD3B2 protein (NP_000189.1, P26439) 
sequence. We obtained the HSD3B2 structural model (based on 
clz45A) from the Phyre2 server [Kelley and Sternberg, 2009], which 
was visualized by the YASARA program (www.yasara.org). 
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